{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T01:39:57Z","timestamp":1793756397313,"version":"4.6.1"},"reference-count":85,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,5,22]],"date-time":"2023-05-22T00:00:00Z","timestamp":1684713600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>\n                    Psoriasis is a common chronic inflammatory skin disease, associated with substantial comorbidity. TH17 lymphocytes, differentiating under the influence of dendritic cell-derived IL-23, and mediating their effects\n                    <jats:italic>via<\/jats:italic>\n                    IL-17A, are believed to be central effector cells in psoriasis. This concept is underlined by the unprecedented efficacy of therapeutics targeting this pathogenetic axis. In recent years, numerous observations made it necessary to revisit and refine this simple \u201clinear\u201d pathogenetic model. It became evident that IL-23 independent cells exist that produce IL-17A, that IL-17 homologues may exhibit synergistic biological effects, and that the blockade of IL-17A alone is clinically less effective compared to the inhibition of several IL-17 homologues. In this review, we will summarize the current knowledge around IL-17A and its five currently known homologues, namely IL-17B, IL-17C, IL-17D, IL-17E (also known as IL-25) and IL-17F, in relation to skin inflammation in general and psoriasis in particular. We will also re-visit the above-mentioned observations and integrate them into a more comprehensive pathogenetic model. This may help to appreciate current as well as developing anti-psoriatic therapies and to prioritize the selection of future drugs\u2019 mode(s) of action.\n                  <\/jats:p>","DOI":"10.3389\/fimmu.2023.1186455","type":"journal-article","created":{"date-parts":[[2023,5,22]],"date-time":"2023-05-22T00:51:03Z","timestamp":1684716663000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":93,"title":["Revisiting the interleukin 17 family of cytokines in psoriasis: pathogenesis and potential targets for innovative therapies"],"prefix":"10.3389","volume":"14","author":[{"given":"Nicolo Costantino","family":"Brembilla","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolf-Henning","family":"Boehncke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,5,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61909-7","article-title":"Psoriasis","volume":"386","author":"Boehncke","year":"2015","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00579","article-title":"Systemic inflammation and cardiovascular comorbidity in psoriasis patients: causes and consequences","volume":"9","author":"Boehncke","year":"2018","journal-title":"Front Immunol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.12024","article-title":"Clinical practice guideline for an integrated approach to comorbidity in patients with psoriasis","volume":"27","author":"Dauden","year":"2013","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1038\/379777a0","article-title":"Pulling the trigger on psoriasis","volume":"379","author":"Boehncke","year":"1996","journal-title":"Nature"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/nature06116","article-title":"Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide","volume":"449","author":"Lande","year":"2007","journal-title":"Nature"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2006.01.001","article-title":"TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells","volume":"24","author":"Veldhoen","year":"2006","journal-title":"Immunity"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01682","article-title":"The IL-17 family of cytokines in psoriasis: IL-17A and beyond","volume":"9","author":"Brembilla","year":"2018","journal-title":"Front Immunol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32549-6","article-title":"Psoriasis","volume":"397","author":"Griffiths","year":"2021","journal-title":"Lancet"},{"key":"B9","doi-asserted-by":"publisher","first-page":"269rv1","DOI":"10.1126\/scitranslmed.3010641","article-title":"Resident memory T cells in human health and disease","volume":"7","author":"Clark","year":"2015","journal-title":"Sci Transl Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.14433","article-title":"The role of IL-23 and the IL-23\/TH 17 immune axis in the pathogenesis and treatment of psoriasis","volume":"31","author":"Girolomoni","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2022.2100219","article-title":"Pathogenesis-oriented therapy of psoriasis using biologics","volume":"22","author":"Boehncke","year":"2022","journal-title":"Expert Opin Biol Ther"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2007.08315.x","article-title":"Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION)","volume":"158","author":"Saurat","year":"2008","journal-title":"Br J Dermatol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0810652","article-title":"Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis","volume":"362","author":"Griffiths","year":"2010","journal-title":"N Engl J Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2015.05.013","article-title":"Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial","volume":"73","author":"Thaci","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31773-8","article-title":"Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial","volume":"394","author":"Reich","year":"2019","journal-title":"Lancet"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2020.0723","article-title":"Efficacy and safety of continuous risankizumab therapy vs treatment withdrawal in patients with moderate to severe plaque psoriasis: a phase 3 randomized clinical trial","volume":"156","author":"Blauvelt","year":"2020","journal-title":"JAMA Dermatol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1016\/j.jid.2021.01.005","article-title":"Differential changes in inflammatory mononuclear phagocyte and T-cell profiles within psoriatic skin during treatment with guselkumab vs. secukinumab","volume":"141","author":"Mehta","year":"2021","journal-title":"J Invest Dermatol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1007\/s11926-021-01005-x","article-title":"Drivers of inflammation in psoriatic arthritis: the old and the new","volume":"23","author":"O\u2019Brien-Gore","year":"2021","journal-title":"Curr Rheumatol Rep"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.15358","article-title":"IL-17A localizes in the exocytic compartment of mast cells in psoriatic skin","volume":"177","author":"Brembilla","year":"2017","journal-title":"Br J Dermatol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1016\/j.jaci.2016.06.038","article-title":"Beta-defensin 2 is a responsive biomarker of IL-17A-driven skin pathology in patients with psoriasis","volume":"139","author":"Kolbinger","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-212127","article-title":"Dual IL-17A and IL-17F neutralisation by bimekizumab in psoriatic arthritis: evidence from preclinical experiments and a randomised placebo-controlled clinical trial that IL-17F contributes to human chronic tissue inflammation","volume":"77","author":"Glatt","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2102383","article-title":"Bimekizumab versus secukinumab in plaque psoriasis","volume":"385","author":"Reich","year":"2021","journal-title":"N Engl J Med"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/dxab075","article-title":"Interleukin-17 family members in health and disease","volume":"33","author":"Chung","year":"2021","journal-title":"Int Immunol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/j.immuni.2020.02.004","article-title":"Structural analysis reveals that the cytokine IL-17F forms a homodimeric complex with receptor IL-17RC to drive IL-17RA-Independent signaling","volume":"52","author":"Goepfert","year":"2020","journal-title":"Immunity"},{"key":"B25","doi-asserted-by":"publisher","first-page":"eaax0687","DOI":"10.1126\/sciimmunol.aax0687","article-title":"Interleukin-17 receptor d: an orphan receptor finds a home in the skin","volume":"4","author":"Billi","year":"2019","journal-title":"Sci Immunol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.aau9657","article-title":"Interleukin-17 receptor d constitutes an alternative receptor for interleukin-17A important in psoriasis-like skin inflammation","volume":"4","author":"Su","year":"2019","journal-title":"Sci Immunol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20202191","article-title":"The metabolism-modulating activity of IL-17 signaling in health and disease","volume":"218","author":"Bechara","year":"2021","journal-title":"J Exp Med"},{"key":"B28","doi-asserted-by":"publisher","first-page":"111489","DOI":"10.1016\/j.celrep.2022.111489","article-title":"IL-17-induced dimerization of IL-17RA drives the formation of the IL-17 signalosome to potentiate signaling","volume":"41","author":"Goepfert","year":"2022","journal-title":"Cell Rep"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2012.456","article-title":"CD8(+) T cells in the lesional skin of atopic dermatitis and psoriasis patients are an important source of IFN-gamma, IL-13, IL-17, and IL-22","volume":"133","author":"Hijnen","year":"2013","journal-title":"J Invest Dermatol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"2426","DOI":"10.1016\/j.jid.2021.03.011","article-title":"PD-1 expression defines epidermal CD8(+)CD103(+) T cells preferentially producing IL-17A and using skewed TCR repertoire in psoriasis","volume":"141","author":"Phadungsaksawasdi","year":"2021","journal-title":"J Invest Dermatol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.585134","article-title":"Interleukin (IL)-12 and IL-18 synergize to promote MAIT cell IL-17A and IL-17F production independently of IL-23 signaling","volume":"11","author":"Cole","year":"2020","journal-title":"Front Immunol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1038\/mi.2013.122","article-title":"IL-17-producing NKT cells depend exclusively on IL-7 for homeostasis and survival","volume":"7","author":"Webster","year":"2014","journal-title":"Mucosal Immunol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2015.09.003","article-title":"Interleukin-23-Independent IL-17 production regulates intestinal epithelial permeability","volume":"43","author":"Lee","year":"2015","journal-title":"Immunity"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.719562","article-title":"Interleukin-17A drives IL-19 and IL-24 expression in skin stromal cells regulating keratinocyte proliferation","volume":"12","author":"Xu","year":"2021","journal-title":"Front Immunol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2022.02.016","article-title":"IL-17A promotes psoriasis-associated keratinocyte proliferation through ACT1-dependent activation of YAP-AREG axis","volume":"142","author":"Yu","year":"2022","journal-title":"J Invest Dermatol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2021.04.021","article-title":"Single-cell transcriptomics applied to emigrating cells from psoriasis elucidate pathogenic versus regulatory immune cell subsets","volume":"148","author":"Kim","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.174.1.164","article-title":"Dysfunctional blood and target tissue CD4+CD25high regulatory T cells in psoriasis: mechanism underlying unrestrained pathogenic effector T cell proliferation","volume":"174","author":"Sugiyama","year":"2005","journal-title":"J Immunol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.jdermsci.2020.09.002","article-title":"A novel role of IL-17A in contributing to the impaired suppressive function of tregs in psoriasis","volume":"101","author":"Liu","year":"2021","journal-title":"J Dermatol Sci"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2005010117","article-title":"CD4 T cell-intrinsic role for the T helper 17 signature cytokine IL-17: effector resistance to immune suppression","volume":"117","author":"Crawford","year":"2020","journal-title":"Proc Natl Acad Sci U.S.A."},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01726","article-title":"Additive or synergistic interactions between IL-17A or IL-17F and TNF or IL-1beta depend on the cell type","volume":"10","author":"Noack","year":"2019","journal-title":"Front Immunol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"35","DOI":"10.3390\/jcm12010035","article-title":"The clinical significance of simultaneous IL-17A and IL-17F blockade in psoriasis non-responding to anti-IL17A therapy","volume":"12","author":"Kokolakis","year":"2022","journal-title":"J Clin Med"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.21617","article-title":"Maintenance of response in moderate-to-severe psoriasis after withdrawal of the interleukin (IL)-17A and IL-17F nanobody sonelokimab: is there a role for IL-17F in disease reoccurrence","volume":"187","author":"Reich","year":"2022","journal-title":"Br J Dermatol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1007\/s11926-022-01084-4","article-title":"Inhibiting IL-17A and IL-17F in rheumatic disease: therapeutics help to elucidate disease mechanisms","volume":"24","author":"Tam","year":"2022","journal-title":"Curr Rheumatol Rep"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1201505","article-title":"Keratinocyte overexpression of IL-17C promotes psoriasiform skin inflammation","volume":"190","author":"Johnston","year":"2013","journal-title":"J Immunol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1038\/ni.2156","article-title":"IL-17C regulates the innate immune function of epithelial cells in an autocrine manner","volume":"12","author":"Ramirez-Carrozzi","year":"2011","journal-title":"Nat Immunol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2018.01.036","article-title":"Neutralization of IL-17C reduces skin inflammation in mouse models of psoriasis and atopic dermatitis","volume":"138","author":"Vandeghinste","year":"2018","journal-title":"J Invest Dermatol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"4983","DOI":"10.3390\/ijms23094983","article-title":"Transcriptomic profiling of peripheral edge of lesions to elucidate the pathogenesis of psoriasis vulgaris","volume":"23","author":"Boonpethkaew","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.20827","article-title":"Bimekizumab for the treatment of moderate-to-severe plaque psoriasis: efficacy, safety, pharmacokinetics, pharmacodynamics and transcriptomics from a phase IIa, randomized, double-blind multicentre study","volume":"186","author":"Oliver","year":"2022","journal-title":"Br J Dermatol"},{"key":"B49","doi-asserted-by":"publisher","first-page":"555","DOI":"10.3390\/ijms23010555","article-title":"IL-17 pathway members as potential biomarkers of effective systemic treatment and cardiovascular disease in patients with moderate-to-Severe psoriasis","volume":"23","author":"Wang","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00718","article-title":"The emerging role of the IL-17B\/IL-17RB pathway in cancer","volume":"11","author":"Bastid","year":"2020","journal-title":"Front Immunol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2008.08902.x","article-title":"Characterization of the interleukin-17 isoforms and receptors in lesional psoriatic skin","volume":"160","author":"Johansen","year":"2009","journal-title":"Br J Dermatol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1159\/000508255","article-title":"IL-17D: a less studied cytokine of IL-17 family","volume":"181","author":"Liu","year":"2020","journal-title":"Int Arch Allergy Immunol"},{"key":"B53","doi-asserted-by":"publisher","first-page":"62","DOI":"10.12703\/r\/10-62","article-title":"Recent advances in palmoplantar pustulosis","volume":"10","author":"Brunasso","year":"2021","journal-title":"Fac Rev"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-022-01339-3","article-title":"IL-17D-induced inhibition of DDX5 expression in keratinocytes amplifies IL-36R-mediated skin inflammation","volume":"23","author":"Ni","year":"2022","journal-title":"Nat Immunol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.986118","article-title":"The potential roles of interleukin-25 in infectious diseases","volume":"13","author":"Wu","year":"2022","journal-title":"Front Immunol"},{"key":"B56","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.jaci.2020.12.628","article-title":"IL-25 (IL-17E) in epithelial immunology and pathophysiology","volume":"148","author":"Borowczyk","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2019.01.021","article-title":"IL-17E (IL-25) enhances innate immune responses during skin inflammation","volume":"139","author":"Senra","year":"2019","journal-title":"J Invest Dermatol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2016.06.009","article-title":"Keratinocyte-derived IL-17E contributes to inflammation in psoriasis","volume":"136","author":"Senra","year":"2016","journal-title":"J Invest Dermatol"},{"key":"B59","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1016\/j.immuni.2018.03.019","article-title":"An interleukin-25-Mediated autoregulatory circuit in keratinocytes plays a pivotal role in psoriatic skin inflammation","volume":"48","author":"Xu","year":"2018","journal-title":"Immunity"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1111\/ced.14988","article-title":"Interleukin-17E, inducible nitric oxide synthase and arginase1 as new biomarkers in the identification of neutrophilic dermatoses","volume":"47","author":"Stalder","year":"2022","journal-title":"Clin Exp Dermatol"},{"key":"B61","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1016\/j.jid.2019.12.013","article-title":"IL-17E (IL-25) and IL-17A differentially affect the functions of human keratinocytes","volume":"140","author":"Borowczyk","year":"2020","journal-title":"J Invest Dermatol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1111\/ajd.13855","article-title":"Serum levels and expression of IL-25 in patients with psoriatic erythroderma","volume":"63","author":"Irie","year":"2022","journal-title":"Australas J Dermatol"},{"key":"B63","doi-asserted-by":"publisher","first-page":"CD011535","DOI":"10.1002\/14651858.CD011535.pub2","article-title":"Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis","volume":"12","author":"Sbidian","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.19341","article-title":"Efficacy and safety of risankizumab vs. secukinumab in patients with moderate-to-severe plaque psoriasis (IMMerge): results from a phase III, randomized, open-label, efficacy-assessor-blinded clinical trial","volume":"184","author":"Warren","year":"2021","journal-title":"Br J Dermatol"},{"key":"B65","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1111\/bjd.15015","article-title":"Candida infections in patients with psoriasis and psoriatic arthritis treated with interleukin-17 inhibitors and their practical management","volume":"177","author":"Saunte","year":"2017","journal-title":"Br J Dermatol"},{"key":"B66","doi-asserted-by":"publisher","first-page":"OOP0258","DOI":"10.1136\/annrheumdis-2022-eular.536","article-title":"IZOKIBEP (ABY-035) in patients with active psoriatic arthritis - 16 week results from a phase 2 study","volume":"81","author":"Behrens","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"B67","volume-title":"DICE therapeutics announces positive topline data from phase 1 clinical trial of lead oral IL-17 antagonist, DC-806, for psoriasis","year":"2022"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01894","article-title":"Bimekizumab, a novel humanized IgG1 antibody that neutralizes both IL-17A and IL-17F","volume":"11","author":"Adams","year":"2020","journal-title":"Front Immunol"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00440-2","article-title":"IL17A\/F nanobody sonelokimab in patients with plaque psoriasis: a multicentre, randomised, placebo-controlled, phase 2b study","volume":"397","author":"Papp","year":"2021","journal-title":"Lancet"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1109017","article-title":"Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis","volume":"366","author":"Papp","year":"2012","journal-title":"N Engl J Med"},{"key":"B71","doi-asserted-by":"publisher","first-page":"adv00683","DOI":"10.2340\/actadv.v102.1993","article-title":"Safety of brodalumab in plaque psoriasis: integrated pooled data from five clinical trials","volume":"102","author":"Reich","year":"2022","journal-title":"Acta Derm Venereol"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.14387","article-title":"Early relapse of psoriasis after stopping brodalumab: a retrospective cohort study in 77 patients","volume":"31","author":"Masson Regnault","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-022-02065-w","article-title":"Number needed to treat network meta-analysis to compare biologic drugs for moderate-to-Severe psoriasis","volume":"39","author":"Leonardi","year":"2022","journal-title":"Adv Ther"},{"key":"B74","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1111\/jdv.15920","article-title":"Systematic review on rapidity of onset of action for interleukin-17 and interleukin-23 inhibitors for psoriasis","volume":"34","author":"Egeberg","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)62113-9","article-title":"Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial","volume":"386","author":"Bachelez","year":"2015","journal-title":"Lancet"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1806382","article-title":"Phase 2 trial of selective tyrosine kinase 2 inhibition in psoriasis","volume":"379","author":"Papp","year":"2018","journal-title":"N Engl J Med"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2011.234","article-title":"Inter-regulation of Th17 cytokines and the IL-36 cytokines in vitro and in vivo: implications in psoriasis pathogenesis","volume":"131","author":"Carrier","year":"2011","journal-title":"J Invest Dermatol"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1111\/ddg.14507","article-title":"German S3-guideline on the treatment of psoriasis vulgaris, adapted from EuroGuiDerm - part 2: treatment monitoring and specific clinical or comorbid situations","volume":"19","author":"Nast","year":"2021","journal-title":"J Dtsch Dermatol Ges"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.16251","article-title":"Association between clinical specialty setting and disease management in patients with psoriatic arthritis: results from LOOP, a cross-sectional, multi-country, observational study","volume":"34","author":"Boehncke","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-217159","article-title":"EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update","volume":"79","author":"Gossec","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-022-00798-0","article-title":"Group for research and assessment of psoriasis and psoriatic arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021","volume":"18","author":"Coates","year":"2022","journal-title":"Nat Rev Rheumatol"},{"key":"B82","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1136\/annrheumdis-2020-218398","article-title":"Points to consider for the treatment of immune-mediated inflammatory diseases with janus kinase inhibitors: a consensus statement","volume":"80","author":"Nash","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-221664","article-title":"Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis","volume":"81","author":"Mease","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"B84","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1080\/1744666X.2020.1857733","article-title":"Guselkumab: the first selective IL-23 inhibitor for active psoriatic arthritis in adults","volume":"17","author":"Boehncke","year":"2021","journal-title":"Expert Rev Clin Immunol"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keab119","article-title":"Comparative effectiveness of guselkumab in psoriatic arthritis: results from systematic literature review and network meta-analysis","volume":"60","author":"Mease","year":"2021","journal-title":"Rheumatol (Oxford)"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1186455\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,22]],"date-time":"2023-05-22T00:51:07Z","timestamp":1684716667000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1186455\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,22]]},"references-count":85,"alternative-id":["10.3389\/fimmu.2023.1186455"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2023.1186455","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,22]]},"article-number":"1186455"}}